Abstract
Preservation of fertility is a key determinant of long-term quality of life of adolescents and young adults treated for curable forms of cancer. The risk of developing primary or secondary infertility after completion of their treatment is variable and difficult to predict. Moreover, evaluation of the extent and reversibility of gonadotoxicity of cancer therapies is currently imperfect, especially in young women.
The term oncofertility was originally coined to describe a new discipline that bridges oncology and reproductive medicine to discover and apply new fertility preservation (FP) options for young patients with cancer. Although there is a great interest in this field, due to the lack of large prospective cohort studies and randomized trials, the level of evidence is higher than III for most of the recommendations.
The most established methods of preserving fertility are sperm banking in men and embryo/oocyte cryopreservation in young women. However, many alternative options, though still experimental, are in development that can already be proposed to young patients in well-defined conditions.
Despite the progress and refinement of FP techniques and the increase in educational resources, an information gap between patients and healthcare teams still persists. Concerted efforts must be made in parallel and global oncofertility programs developed to offer high-quality techniques to meet this unique need in young patients with cancer.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N. Surviving childhood and reproductive-age malignancy: effects on fertility and future parenthood. Lancet Oncol. 2010;11(5):490–8.
Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol. 2010;28(32):4831–41.
Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, et al. Cancer and fertility program improves patient satisfaction with information received. J Clin Oncol. 2016;34(15):1780–6.
Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med. 2009;360(9):902–11.
Peate M, Meiser B, Friedlander M, Zorbas H, Rovelli S, Sansom-Daly U, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer – an Australian fertility decision aid collaborative group study. J Clin Oncol. 2011;29(13):1670–7.
Katz DJ, Kolon TF, Feldman DR, Mulhall JP. Fertility preservation strategies for male patients with cancer. Nat Rev Urol. 2013;10(8):463–72.
Hsiao W, Stahl PJ, Osterberg EC, Nejat E, Palermo GD, Rosenwaks Z, et al. Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction the Weill Cornell experience. J Clin Oncol. 2011;29(12):1607–11.
Stahl O, Boyd HA, Giwercman A, Lindholm M, Jensen A, Kjaer SK, et al. Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst. 2011;103(5):398–406.
Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14:1–16.
Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010;116(13):3102–11.
Reh A, Oktem O. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635–9.
Iwase A, Nakamura T, Nakahara T, Goto M, Kikkawa F. Anti-Mullerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review. Reprod Sci. 2015;22(5):519–26.
Loren AW, Mangu PB, Beck LN, Brennan L, Madgalinsky AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.
Peccatori FA, Azim HA Jr, Orecchia R, Hokestra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practical guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–70.
Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011;95(6):2125.e9–11.
Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment as ovarian stimulation in woman with breast cancer. J Clin Oncol. 2015;33(22):2424–9.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.
Goldrat O, Kroman N, Peccatori FA, Cordoba O, Pistilli B, Lidegaard O, et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur J Cancer. 2015;51(12):1490–6.
Donnez J, Dolamnm M. Fertility preservation in women. N Engl J Med. 2017;377:1657–65.
Donnez J, Dolmans M-M, Pellicer A, Diaz-Garcia C, Ernst E, Macklon KT, et al. Fertility preservation for age-related fertility decline. Lancet. 2015;385(9967):506–7.
Andersen CY. Success and challenges in fertility preservation after ovarian tissue grafting. Lancet. 2015;6/8(9981):1947–8.
Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010;116(16):2908–14.
Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, et al. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95(6):2158–61.
Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.
Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El-Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2011;95(3):906–14.e1–4.
Lambertini M, Ceppi M, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–19.
Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. 2010;21(10):2052–60.
Demeestere I, Brice P, Fedro A, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of the gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long – term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568–74.
Quinn GP, Vadaparampil ST, Lee JH, Jacobsen PB, Bepler G, Lancaster J, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–7.
Quinn GP, Vadaparampil ST, Malo T, Reinecke J, Bower B, Albrecht T, et al. Oncologists’ use of patient educational materials about cancer and fertility preservation. Psychooncology. 2012;21(11):1244–9. https://doi.org/10.1002/pon.2022.
Letourneau JM, Ebbel EE, Katz PP, Katz A, Ai WZ, Chien AJ, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2011;118(6):1710–7. https://doi.org/10.1002/cncr.26459.
Azim HA Jr, Santoro L, Pavlidis N, Gelber S, Kroman N, Azim H, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011;47(1):74–83.
Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameyne L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–9.
Fournier EM. Oncofertility and the rights to future fertility. JAMA Oncol. 2016;2(2):249–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Caroline, D., Ries, F. (2018). Preservation of Fertility in the Cancer Patient. In: Dicato, M., Van Cutsem, E. (eds) Side Effects of Medical Cancer Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-70253-7_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-70253-7_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-70252-0
Online ISBN: 978-3-319-70253-7
eBook Packages: MedicineMedicine (R0)